Eupraxia Pharmaceuticals (NASDAQ:EPRX) Stock Rating Upgraded by Wall Street Zen

Eupraxia Pharmaceuticals (NASDAQ:EPRX) was upgraded by Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued on Saturday, Wall Street Zen reports.

Several other analysts have also issued reports on EPRX. Cantor Fitzgerald restated an “overweight” rating on shares of Eupraxia Pharmaceuticals in a report on Wednesday, July 15th. Stifel Nicolaus assumed coverage on shares of Eupraxia Pharmaceuticals in a research note on Thursday, May 21st. They set a “buy” rating and a $25.00 target price for the company. Oppenheimer assumed coverage on shares of Eupraxia Pharmaceuticals in a research report on Thursday, June 25th. They set an “outperform” rating and a $17.00 price target for the company. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Eupraxia Pharmaceuticals in a report on Friday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $18.00.

Eupraxia Pharmaceuticals Price Performance

NASDAQ:EPRX opened at $8.42 on Friday. Eupraxia Pharmaceuticals has a 52 week low of $5.16 and a 52 week high of $9.32. The company has a quick ratio of 16.00, a current ratio of 16.00 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $547.47 million, a P/E ratio of -8.25 and a beta of 1.07. The stock’s fifty day moving average is $6.84 and its two-hundred day moving average is $6.99.

Eupraxia Pharmaceuticals (NASDAQ:EPRX) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.25) by $0.02. Equities analysts expect that Eupraxia Pharmaceuticals will post -0.85 EPS for the current year.

Hedge Funds Weigh In On Eupraxia Pharmaceuticals

Several hedge funds have recently bought and sold shares of EPRX. Affinity Asset Advisors LLC boosted its holdings in Eupraxia Pharmaceuticals by 429.7% during the 1st quarter. Affinity Asset Advisors LLC now owns 1,589,005 shares of the company’s stock valued at $11,504,000 after acquiring an additional 1,289,005 shares during the period. Vivo Capital LLC purchased a new stake in Eupraxia Pharmaceuticals during the third quarter worth about $7,965,000. Jupiter Topco LLC purchased a new stake in Eupraxia Pharmaceuticals during the second quarter worth about $6,851,000. Seven Fleet Capital Management LP purchased a new stake in Eupraxia Pharmaceuticals during the first quarter worth about $5,137,000. Finally, Redmile Group LLC acquired a new stake in shares of Eupraxia Pharmaceuticals during the first quarter worth about $5,068,000.

Eupraxia Pharmaceuticals Company Profile

Eupraxia Pharmaceuticals Inc (NASDAQ:EPRX) is a clinical-stage biotechnology company based in Canada. The company develops locally administered therapies intended to treat inflammatory, fibrotic and other diseases while limiting patients’ exposure to medication throughout the body.

Eupraxia’s development programs are built around its proprietary Diffusion Driven Drug Delivery (3D) platform. The technology is designed to provide controlled, sustained release of pharmaceutical compounds at targeted sites, potentially extending treatment effects and reducing systemic side effects.

The company’s lead product candidate, EP-104I, is an extended-release formulation of fluticasone propionate being developed for intra-articular administration in patients with osteoarthritis of the knee.